Dividends Inside 
Salarius Pharmaceuticals, Inc.
DCOY
$7.02 (- $0.23 - 3.17%)
Last updated: 2026-07-08 14:27 UTC
Salarius Pharmaceuticals, Inc. trades under ticker DCOY on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US79400X6022, CUSIP 79400X602. Also searched as Salarius Pharmaceuticals.
Related researchDCOY stock priceDCOY share priceSalarius Pharmaceuticals stockSalarius Pharmaceuticals share price79400X602
About the Company
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer who have limited treatment options. The company’s primary activity centers on discovering and advancing novel small-molecule and peptide-based drug candidates targeting difficult-to-treat malignancies. Its portfolio includes investigational therapies designed to modulate epigenetic and protein-degradation pathways, aiming to address hematologic cancers and solid tumors where existing treatments are inadequate. Salarius Pharmaceuticals operates today in the context of its combination with Decoy Therapeutics, whose AI- and machine learning–enabled platform is used to design and engineer next-generation peptide-conjugate drug candidates. This platform is applied to areas of high unmet medical need, including respiratory viral diseases and gastrointestinal cancers. Headquartered in Houston, Texas, with related research activities connected to hubs such as Cambridge, Massachusetts and New York, the company participates in the broader oncology and antiviral drug development ecosystem, working alongside academic centers, clinical investigators, and industry partners to move its pipeline through preclinical and early clinical development.
Price History
Latest News for DCOY
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral mechanisms using its proprietary peptide conjugate platform, IMP3ACT™, today announced that members of its executive leadership will present across two leading peptide therapeutics conferences in Boston the week of April 27, 2026.
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today highlighted a series of recent strategic, operational and scientific achievements that underscore accelerating momentum and a clear trajectory toward becoming a clinical-stage company. The Company also outlined upcoming milestones that are expected to drive shareholder value.
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, announced that Rick Pierce, Chief Executive Officer of Decoy, will participate in a Virtual Investor Closing Bell event on Thursday, April 9, 2026, at 4:00 PM ET.
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq Capital Market.
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically inc
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m. Eastern Time, on March 6, 2026. Beginning with the opening of trading on March 9, 2026, Decoy's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X602.